Cargando…

Energy expenditure in myelofibrosis patients treated with a JAK1/2 inhibitor

Weight gain is a known adverse effect of ruxolitinib, a JAK1/2 inhibitor that is the mainstay of treatment for many patients with myelofibrosis. The mechanisms behind weight increase with ruxolitinib is incompletely understood, although decreased adipose tissue lipolysis and increased appetite due t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tremblay, Douglas, Dougherty, Mikaela, Mascarenhas, John, Gallagher, Emily Jane
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339379/ https://www.ncbi.nlm.nih.gov/pubmed/37455900 http://dx.doi.org/10.3389/fendo.2023.1141029

Ejemplares similares

The clinical dilemma of JAK inhibitor failure in myelofibrosis: Predictive characteristics and outcomes
por: Mascarenhas, John O., et al.
Publicado: (2022)

Next Generation Therapeutics for the Treatment of Myelofibrosis
por: Tremblay, Douglas, et al.
Publicado: (2021)

Clinical Utility of Fedratinib in Myelofibrosis
por: Waksal, Julian A, et al.
Publicado: (2021)

Will JAK1/2 inhibitors change the standard of care for myelofibrosis?
por: Jung, Chul Won
Publicado: (2012)

Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
por: Pardanani, A, et al.
Publicado: (2013)

Treatment and management of myelofibrosis in the era of JAK inhibitors
por: Keohane, Clodagh, et al.
Publicado: (2013)

Treatment and management of myelofibrosis in the era of JAK inhibitors [Corrigendum]
Publicado: (2013)

The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation
por: Ikeda, Kazuhiko, et al.
Publicado: (2017)

Cutaneous cryptococcosis in a patient with myelofibrosis receiving JAK‐inhibitor
por: Chen, Jui‐Che, et al.
Publicado: (2021)

P1070: NAVITOCLAX MONOTHERAPY IN PATIENTS WITH MYELOFIBROSIS PREVIOUSLY TREATED WITH JAK-2 INHIBITORS: SAFETY AND TOLERABILITY
por: Pullarkat, V., et al.
Publicado: (2022)

Metabolic Effects of JAK1/2 Inhibition in Patients with Myeloproliferative Neoplasms
por: Sapre, Manali, et al.
Publicado: (2019)

Many questions raised by a question on JAK1/2 inhibitors in primary myelofibrosis
por: Raut, Lalit
Publicado: (2013)

Myelofibrosis in 2019: moving beyond JAK2 inhibition
por: Schieber, Michael, et al.
Publicado: (2019)

Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis
por: Tvorogov, Denis, et al.
Publicado: (2018)

Finding a Jill for JAK: Assessing Past, Present, and Future JAK Inhibitor Combination Approaches in Myelofibrosis
por: Kuykendall, Andrew T., et al.
Publicado: (2020)

Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis
por: Tefferi, Ayalew, et al.
Publicado: (2023)

The odyssey of pacritinib in myelofibrosis
por: Venugopal, Sangeetha, et al.
Publicado: (2022)

MicroRNA Regulation of Brown Adipogenesis and Thermogenic Energy Expenditure
por: Shamsi, Farnaz, et al.
Publicado: (2017)

Acute effect of propranolol on resting energy expenditure in hyperthyroid patients
por: Senn, Jaël Rut, et al.
Publicado: (2023)

Risk‐adjusted safety analysis of the oral JAK2/IRAK1 inhibitor pacritinib in patients with myelofibrosis
por: Pemmaraju, Naveen, et al.
Publicado: (2022)

SAT-091 Metabolic Effects of JAK1/2 Inhibition in Patients with Myeloproliferative Neoplasms
por: Sapre, Manali, et al.
Publicado: (2019)

Prediction of resting energy expenditure in Italian older adults with severe obesity
por: Danielewicz, Ana Lúcia, et al.
Publicado: (2023)

PB2225: A RANDOMIZED OPEN-LABEL, PHASE 3 STUDY OF IMETELSTAT VS BEST AVAILABLE THERAPY IN INTERMEDIATE-2 OR HIGH-RISK MYELOFIBROSIS RELAPSED/REFRACTORY TO JAK INHIBITOR (IMPACTMF)
por: Mascarenhas, John, et al.
Publicado: (2023)

Nephrotic syndrome in primary myelofibrosis with renal extramedullary hematopoiesis and glomerulopathy in the JAK inhibitor era
por: Del Sordo, Rachele, et al.
Publicado: (2017)

β-Adrenoceptor Signaling Networks in Adipocytes for Recruiting Stored Fat and Energy Expenditure
por: Collins, Sheila
Publicado: (2012)

Central regulation of food intake, body weight, energy expenditure, and glucose homeostasis
por: Scott, Michael M., et al.
Publicado: (2014)

JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives
por: Bose, Prithviraj, et al.
Publicado: (2020)

Non-Mammalian Vertebrates: Distinct Models to Assess the Role of Ion Gradients in Energy Expenditure
por: Geisler, Caroline E., et al.
Publicado: (2017)

The Janus Kinase (JAK) FERM and SH2 Domains: Bringing Specificity to JAK–Receptor Interactions
por: Ferrao, Ryan, et al.
Publicado: (2017)

Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis
por: Jamieson, Catriona, et al.
Publicado: (2015)

Rapid Emergence of Chronic Lymphocytic Leukemia During JAK2 Inhibitor Therapy in a Patient With Myelofibrosis
por: Sousos, Nikolaos, et al.
Publicado: (2020)

Resting Energy Expenditure, Insulin Resistance and UCP1 Expression in Human Subcutaneous and Visceral Adipose Tissue of Patients With Obesity
por: Bettini, Silvia, et al.
Publicado: (2019)

Emerging Treatment Options for Myelofibrosis: Focus on Anemia
por: Sastow, Dahniel, et al.
Publicado: (2023)

Morphological and Immunophenotypical Changes of Human Bone Marrow Adipocytes in Marrow Metastasis and Myelofibrosis
por: Dello Spedale Venti, Michele, et al.
Publicado: (2022)

Germline-somatic JAK2 interactions are associated with clonal expansion in myelofibrosis
por: Brown, Derek W., et al.
Publicado: (2022)

Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor
por: Gangat, Naseema, et al.
Publicado: (2023)

Preconceptional, Gestational, and Lactational Exposure to an Unconventional Oil and Gas Chemical Mixture Alters Energy Expenditure in Adult Female Mice
por: Balise, Victoria D., et al.
Publicado: (2019)

Analysis of Predictive Equations for Estimating Resting Energy Expenditure in a Large Cohort of Morbidly Obese Patients
por: Cancello, Raffaella, et al.
Publicado: (2018)

Kynurenic Acid Acts as a Signaling Molecule Regulating Energy Expenditure and Is Closely Associated With Metabolic Diseases
por: Zhen, Delong, et al.
Publicado: (2022)

The role of allogeneic stem-cell transplant in myelofibrosis in the era of JAK inhibitors: a case-based review
por: Tiribelli, Mario, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_s5to6apmbd57j6rnpdf0s5pd3p